Gabapentin Tablet
Product Images NDC 71205-533

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-533). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-533-90 (Gabapentin 600mg 100tab)

Gabapentin 600 mg tablets label by Proficient Rx LP. The label indicates a quantity of 90 tablets, each film-coated and containing 600 mg of gabapentin. The label includes the NDC 71205-533-90 and manufacturer SciGen Pharmaceuticals, Inc. Additional details mention tablet physical characteristics and storage temperature instructions (20°-25°C).*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over an 8-week period during a study with Gabapentin at 3600 mg/day compared to placebo. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10. Gabapentin shows a declining mean pain score over time while placebo remains relatively constant.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over 7 weeks comparing placebo and gabapentin treatments at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Gabapentin groups show a decrease in mean pain score compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' presenting results from two studies. The y-axis shows percentage from 0% to 100%. Study 1 compares placebo (PBO) with gabapentin (GBP) 3600 mg, showing 12% and 29% responder rates respectively. Study 2 compares placebo with gabapentin 1800 mg and 2400 mg, showing 14%, 32%, and 34% responder rates respectively. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

A formula for calculating creatinine clearance (CLCr) is shown, incorporating age, weight, serum creatinine, and a factor of 0.85 for female patients. This formula is commonly used in clinical settings to estimate kidney function.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin shown as a molecular diagram with a cyclohexane ring and side chains including amine and carboxyl groups, representing the active ingredient gabapentin.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing the percentage difference versus daily dose in mg for three different studies (a, b, and c). The x-axis represents daily dose values of 600, 900, 1200, and 1800 mg; the y-axis represents percentage difference from 2 to 22%. Each study is represented by different symbols and colors, illustrating data points for each dose in the studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.